The Precision Peptide Company Inc. is a listed company. Filings by its managers are published through SEDI. Over the twelve months to 23 October 2026, 7 filings were filed, from 1 insider.
The flow runs one way only: 1 insider bought (2 purchases totalling €25k) and nobody sold on the market. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The largest single trade was a purchase of €21k by Sandhu, Pratapvir, published on 17 July 2026. Those buying include 1 senior executive.
The last insider purchase was made public on 17 July 2026, 101 days ago. Filings reach the SEDI feed a median of 53 days after the trade. Until a filing is published, the market cannot know about the trade.
With 7 filings in twelve months, the company is quieter than the median of 12 filings across the 2,471 companies we follow on the same exchange. Looking back to 2026, when coverage begins, insiders filed 2 purchases and no sales.
Source: insider filings from SEDI. Past trades are no guide to future returns.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
· cache
7 of 7 declarations
The Precision Peptide Company Inc. is a company focused on the development and manufacturing of peptides for pharmaceutical and biotechnology applications. It is listed on the Toronto Stock Exchange (XTSE).